Hyperkalemia Management

Introduction to Hyperkalemia Therapy

Hyperkalemia can be effectively managed with Lokelma (sodium zirconium cyclosilicate), which lowers serum potassium by approximately 0.7 mEq/L within 2 hours, as recommended by the American Heart Association and the American College of Emergency Physicians 1

The recommended dosage for acute hyperkalemia is 10g three times daily for 48 hours, followed by maintenance therapy starting with 5g once daily, as recommended by the European Renal Association and the American Heart Association 1
After achieving normal potassium levels, the starting dose is 5 g once daily, with a minimum effective dose of 5 g once daily and a maximum dose of 15 g once daily, which can be titrated based on serum potassium monitoring 1
Lokelma should be continued indefinitely as maintenance therapy in patients with kidney failure after achieving normal potassium levels, with regular monitoring to adjust dosing as needed, according to the Kidney International guideline 2

Temporarily withhold Lokelma during prolonged fasting, surgery, or critical medical illness, as recommended by the Kidney International guideline 2
Lokelma has a faster onset of action, working within 1 hour compared to patiromer's 7-hour onset, as noted by the National Kidney Foundation 1
Sodium zirconium cyclosilicate has a more rapid onset of action (within 1 hour) compared to patiromer (approximately 7 hours) in patients with hyperkalemia, with a moderate strength of evidence 1

Regular monitoring of serum potassium is recommended, with checks within 2-4 hours after initial treatment, within 1 week of any dose adjustment, and regularly based on risk factors and comorbidities, to maintain mean serum potassium at approximately 4.5 mEq/L with 10 g daily 1
Dose-dependent edema, particularly with 15g daily dosing, is a common adverse effect of Lokelma, as reported by the FDA 1
The use of Lokelma is associated with a risk of hypokalemia, with 10% of patients experiencing hypokalemia with 10 g daily and 11% with 15 g daily, and is contraindicated in patients with severe constipation, bowel obstruction or impaction 1

Once-daily 5 g or 10 g sodium zirconium cyclosilicate dose effectively maintained normokalemia over 14 to 28 days in patients with chronic hyperkalemia, based on moderate-strength evidence 1
Long-term studies show efficacy of sodium zirconium cyclosilicate maintained for up to 12 months in patients with hyperkalemia, with a low strength of evidence 1
The expected response to Lokelma includes normalization of potassium in 84% of patients within 24 hours and 98% of patients within 48 hours, with an onset of action beginning within 1 hour, based on high-strength evidence 1
The 10 g maintenance dose has been shown to maintain mean serum potassium at approximately 4.5 mEq/L, while the 5 g dose maintains levels at approximately 4.8 mEq/L over 28 days, with a moderate strength of evidence 1

Lokelma may provide added benefit for patients with metabolic acidosis due to sustained increases in serum bicarbonate, as suggested by the American Society of Nephrology and based on low-strength evidence 1
Sodium zirconium cyclosilicate may provide an added benefit for patients with metabolic acidosis due to sustained increases in serum bicarbonate, with a low strength of evidence 1